Biomarkers are incorporated into cross-sectional, case-control and prospective cohort studies of occupational causes of cancer in order to enhance exposure assessment, provide insight into early biologic effects of specific chemicals, evaluate sources of genetic susceptibility and classify tumors at the molecular level to identify subgroups that may be more etiologically homogenous. A cross-sectional study of healthy workers exposed to benzene in Shanghai, China showed that exposed workers had elevated levels of chromosomal aberrations in peripheral lymphocytes, similar to the type observed in patients with chemically associated leukemias, and elevated levels of benzene oxide-albumin and hemoglobin adducts. A pilot study of pesticide applicators exposed to 2,4-D found that the lymphocyte replicative index was elevated in post-exposure compared with pre-exposure blood samples. A study of U.S. army soldiers deployed to Kuwait close to oil well fires in the aftermath of the Gulf War showed that various biomarkers of PAH exposure were not elevated during deployment compared to pre- and post-deployment samples collected while soldiers were stationed in Germany. Newly developed and on-going case-control studies of stomach, esophagus, brain, bladder and breast cancer, NHL, and benzene-induced hematotoxicity and hematologic malignancies and cohort studies of women in China and agricultural workers in the United States are evaluating a range of potential genetic risk factors and their interaction with occupational and environmental exposures. Most of these studies are also collecting tumor samples for future molecular analyses. In a study using the tumor tissue of 106 life-time nonsmoking women with lung cancer a signifcant gene-environment interaction was found between the GSTM-1 (Null) geneotype and environmental tobacco smoke.

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Epidemiology And Genetics (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CP010121-05
Application #
6433287
Study Section
(OEB)
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Cancer Epidemiology and Genetics
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Buchacz, Kate; Lau, Bryan; Jing, Yuezhou et al. (2016) Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis 214:862-72
Moore, Lee E; Pfeiffer, Ruth M; Poscablo, Cristina et al. (2008) Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 9:359-66
Samanic, C M; Kogevinas, M; Silverman, D T et al. (2008) Occupation and bladder cancer in a hospital-based case-control study in Spain. Occup Environ Med 65:347-53
Purdue, Mark P; Lan, Qing; Kricker, Anne et al. (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28:704-12
Lan, Qing; Zheng, Tongzhang; Chanock, Stephen et al. (2007) Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28:823-7
Villanueva, Cristina M; Cantor, Kenneth P; Grimalt, Joan O et al. (2007) Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol 165:148-56
Yokley, Karen; Tran, Hien T; Pekari, Kaija et al. (2006) Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach. Risk Anal 26:925-43
Liu, Yang; Lan, Qing; Siegfried, Jill M et al. (2006) Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8:46-51
Raimondi, S; Paracchini, V; Autrup, H et al. (2006) Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review. Am J Epidemiol 164:1027-42
Choi, Ji-Yeob; Lee, Kyoung-Mu; Noh, Dong-Young et al. (2006) Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 100:213-8

Showing the most recent 10 out of 24 publications